PMID- 29123173
OWN - NLM
STAT- MEDLINE
DCOM- 20190705
LR  - 20220321
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Nov 9
TI  - Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B 
      activity in overweight/obese adults: a randomized placebo-controlled trial.
PG  - 15154
LID - 10.1038/s41598-017-15264-1 [doi]
LID - 15154
AB  - In-vitro studies suggest that vitamin D reduces inflammation by inhibiting 
      nuclear factor kappa-B (NFkappaB) activity. Yet, no trials have examined the effects 
      of vitamin D supplementation on NFkappaB activity in-vivo in humans. We conducted a 
      double-blind randomized trial (RCT) examining effects of vitamin D 
      supplementation on inflammatory markers and NFkappaB activity in peripheral blood 
      mononuclear cells (PBMCs). Sixty-five overweight/obese, vitamin D-deficient 
      (25-hydroxyvitamin D [25(OH)D] </= 50 nmol/L) adults were randomized to a single 
      100,000 IU bolus followed by 4,000 IU daily cholecalciferol or matching placebo 
      for 16 weeks. We measured BMI, % body fat, serum 25(OH)D, high-sensitivity 
      C-reactive protein (hsCRP), tumour necrosis factor (TNF), monocyte 
      chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-gamma), several 
      interleukins, and NFkappaB activity in PBMCs. Fifty-four participants completed the 
      study. Serum 25(OH)D concentrations increased with vitamin D supplementation 
      compared to placebo (p < 0.001). Vitamin D and placebo groups did not differ in 
      any inflammatory markers or NFkappaB activity (all p > 0.05). Results remained 
      non-significant after adjustment for age, sex, and % body fat, and after further 
      adjustment for sun exposure, physical activity, and dietary vitamin D intake. 
      Although in-vitro studies report anti-inflammatory effects of vitamin D, our RCT 
      data show no effect of vitamin D supplementation on inflammatory markers or NFkappaB 
      activity in-vivo in humans.
FAU - Mousa, Aya
AU  - Mousa A
AD  - Monash University, Monash Centre for Health Research and Implementation (MCHRI), 
      Melbourne, VIC 3168, Australia.
FAU - Naderpoor, Negar
AU  - Naderpoor N
AD  - Monash University, Monash Centre for Health Research and Implementation (MCHRI), 
      Melbourne, VIC 3168, Australia.
FAU - Johnson, Josphin
AU  - Johnson J
AUID- ORCID: 0000-0002-2243-012X
AD  - Monash University, Monash Centre for Health Research and Implementation (MCHRI), 
      Melbourne, VIC 3168, Australia.
FAU - Sourris, Karly
AU  - Sourris K
AD  - Baker IDI Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
FAU - de Courten, Maximilian P J
AU  - de Courten MPJ
AD  - Victoria University, Centre for Chronic Disease, Melbourne, VIC 3021, Australia.
FAU - Wilson, Kirsty
AU  - Wilson K
AD  - Monash University, Department of Immunology and Pathology, Melbourne, VIC 3004, 
      Australia.
FAU - Scragg, Robert
AU  - Scragg R
AD  - The University of Auckland, School of Population Health, Auckland, 1072, New 
      Zealand.
FAU - Plebanski, Magdalena
AU  - Plebanski M
AD  - Monash University, Department of Immunology and Pathology, Melbourne, VIC 3004, 
      Australia.
FAU - de Courten, Barbora
AU  - de Courten B
AD  - Monash University, Monash Centre for Health Research and Implementation (MCHRI), 
      Melbourne, VIC 3168, Australia. barbora.decourten@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171109
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - 0 (Placebos)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Australia
MH  - Blood Chemical Analysis
MH  - Cytokines/analysis
MH  - Double-Blind Method
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Inflammation/*pathology
MH  - Leukocytes, Mononuclear/chemistry
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Obesity/*complications
MH  - Placebos/administration & dosage
MH  - Treatment Outcome
MH  - Vitamin D/*administration & dosage
PMC - PMC5680306
COIS- The authors declare that they have no competing interests.
EDAT- 2017/11/11 06:00
MHDA- 2019/07/06 06:00
PMCR- 2017/11/09
CRDT- 2017/11/11 06:00
PHST- 2017/06/19 00:00 [received]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2017/11/11 06:00 [entrez]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2019/07/06 06:00 [medline]
PHST- 2017/11/09 00:00 [pmc-release]
AID - 10.1038/s41598-017-15264-1 [pii]
AID - 15264 [pii]
AID - 10.1038/s41598-017-15264-1 [doi]
PST - epublish
SO  - Sci Rep. 2017 Nov 9;7(1):15154. doi: 10.1038/s41598-017-15264-1.